Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-hour versus 24-hour magnesium sulphate maintenance for seizure prevention in severe pre-eclampsia and eclampsia
PACTR202503856206635Phase 0Not yet recruiting
- Sponsor
- Alfa Yusuf
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 0, randomised, open-label trial of magnesium sulfate in preeclampsia, eclampsia and maternal hypertension (HDP) (2 arms), sponsored by Alfa Yusuf. Primary endpoint: Occurrence of seizures. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
magnesium sulfate
03
Conditions
preeclampsiaeclampsiamaternal hypertension (HDP)
Beyond the preview
Go deeper on PACTR202503856206635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202503856206635.